AI-driven biotechnology company Tres Alchemix has closed its $4.4 million Series A financing round, the company has announced. 

New funding will be used to accelerate the development of Tres Alchemix’s predictive AI platform and support the opening of a new laboratory at The Oxford Science Park, a hub of world-leading science and technology companies. 

Tres Alchemix was co-founded in 2023 by three DPhil (PhD) graduates of the University of Oxford. It aims to develop advanced technologies integrating multi-omic and multimodal big data with proprietary quantum-chemical calculation methods to build predictive models of biological and biochemical processes in the human body.  

These human in silico models forecast how new drugs will behave in the body, capturing both therapeutic effects and side effects. This capability enables the design of novel small-molecule candidates that maximise efficacy while minimising risk. 

“We believe our technology can be a game changer for the drug-discovery field,” said Hisashi Hashimoto, Co-Founder and CEO of Tres Alchemix. “Our models can accurately predict drug effects and potential side effects and can even propose new compounds tailored to disease biology. This allows us to compress, or even bypass, the time-consuming hit-discovery phase while lowering the risk of late-stage clinical failure.” 

Akira Kurabayashi, Managing Partner and Head of Japan at DNX Ventures, who invested in Tres Alchemix, said DNX is “excited to lead the investment”. 

“We believe that the innovative methodology developed by these three (“Tres”) scientists will play a leading role in transforming global drug development,” added Yoshiki Shiraishi, Partner at DNX Ventures.

Bruno Quinney, Content Team, DDW